#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mantle cell lymphoma Gastrointestinal disorder Ichthyosis Pleural mesothelioma Malignant fibrous histiocytoma Superficial vein thrombosis Arterial tortuosity syndrome Central nervous system neoplasm Hypocalcaemia Cortical dysplasia Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome Anti-HLA antibody test positive Growth hormone deficiency Breast cancer Thalassaemia More trials…

    Learn about Rare Diseases

    Hyperoxaluria – Treatment Methylmalonic acidaemia – Basic Information X-linked lymphoproliferative syndrome – Trials in Disease Marginal zone lymphoma – Life with Disease Sarcoidosis – Diagnostics Uterine leiomyosarcoma – Life with Disease KBG syndrome Burkitt’s lymphoma – Diagnostics Congenital hypotransferrinaemia – Diagnostics Pleomorphic leiomyosarcoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Orismilast Pramlintide Acetate Insulin Lispro TETANUS TOXOID Asp1570 Azd5863 Eptinezumab Aceclofenac Pelacarsen Mavacamten YL201 SODIUM FUSIDATE Naxitamab Trehalose Dihydrate (Ph.eur.) Trametinib Rosnilimab Aciclovir Verapamil Agomelatine Troriluzole More therapies…

    Learn about Your Condition

    Influenza Hepatitis alcoholic Gastrointestinal carcinoma Alveolar rhabdomyosarcoma Meniscus operation Endometrial cancer recurrent Vascular calcification Kidney transplant rejection Arterial tortuosity syndrome Corneal dystrophy Mitochondrial myopathy Spinal cord injury Haemorrhage intracranial Polymyositis Sjogren's syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Mmfoiq Zgtahdkc Kqvxb 2dc Dyejrsxec 4rfbn Hipvzov

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency

    Not recruiting

    4 1 1 1
    Investigated Drugs:
    • Favezelimab
    • Quavonlimab
    • Vibostolimab
    Belgium Denmark Estonia France Germany Greece +7

  • Study of Belrestotug and Dostarlimab for Patients with Untreated Advanced Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Human Igg1 Kappa Monoclonal Antibody Against Tigit
    • Dostarlimab
    • Pembrolizumab
    Belgium Bulgaria Croatia Czechia Estonia Finland +14

  • Study on BI 764524 for Patients with Moderate to Severe Diabetic Retinopathy

    Not recruiting

    2 1
    Investigated Drugs:
    • Bi 764524
    Germany Hungary Italy Poland Spain

  • Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome

    Not recruiting

    2 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • Vib1116
    Austria Bulgaria France Germany Greece Hungary +5

  • Study on VE202 for Patients with Mild-to-Moderate Ulcerative Colitis

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Bacilli, Cluster Xviii, Strain Relative Thomasclavelia Ramosum, Live
    • Bacilli, Cluster Xviii, Strain Relative Thomasclavelia Sp000508865, Live
    • Clostridia, Cluster Iv, Strain Relative Anaerotruncus Colihominis, Live
    Bulgaria Czechia Hungary Lithuania The Netherlands Poland

  • Study of Rocatinlimab in Adults with Prurigo Nodularis Not Adequately Controlled by Topical Treatments

    Not recruiting

    3 1
    Investigated Drugs:
    • Rocatinlimab
    Austria Belgium Finland France Germany Greece +9

  • Study of cabozantinib with atezolizumab compared to sorafenib in untreated patients with advanced liver cancer (hepatocellular carcinoma)

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Sorafenib
    • Atezolizumab
    • Cabozantinib
    Belgium France Hungary Romania Spain

  • Study on Norucholic Acid for Treating Primary Sclerosing Cholangitis in Patients

    Not recruiting

    3 1
    Investigated Diseases:
    • Cholangitis sclerosing
    Investigated Drugs:
    • Norucholic Acid
    Austria Denmark Finland France Germany Hungary +3

  • Study on EYE103 and Ranibizumab for Patients with Diabetic Macular Edema

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Macular oedema
    • Diabetic retinal oedema
    Investigated Drugs:
    • Eye103
    • Fluorescein Sodium
    • Ranibizumab
    Austria Croatia Czechia France Germany Hungary +6

  • Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Active Axial Spondyloarthritis

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Bimekizumab
    Belgium Czechia France Germany Hungary Poland +1
Previous Page
1 … 48 49 50 51 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!